Related Experiment Video
Updated: Jun 25, 2025
07:12
Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
3.6K
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv1, Pengbing Mi2, Jeffrey J Babon3
1Center for Molecular Biosciences and Non-Communicable Diseases Research, Xi'an University of Science and Technology, Xi'an, Shaanxi 710054, China; Xi'an Amazinggene Co., Ltd, Xi'an, Shaanxi 710026, China.
Pharmacological Research
|May 22, 2024
Summary
The Janus kinase-STAT pathway is crucial for cell signaling and homeostasis. This review details drug discovery strategies targeting this pathway for treating diseases like cancer and autoimmune disorders.
Area of Science:
- Molecular Biology
- Immunology
- Pharmacology
Background:
- The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is vital for cytokine signaling, influencing hematopoiesis, immune balance, and tissue homeostasis.
- Dysregulation of the JAK-STAT pathway is linked to immunodeficiency, autoimmune diseases, hematological disorders, and cancers.
Purpose of the Study:
- To review and consolidate key drug discovery strategies targeting the JAK-STAT pathway.
- To advance the understanding of small molecule interventions for JAK-STAT signaling-related diseases.
Main Methods:
- Literature review of JAK-STAT pathway research and drug development.
- Analysis of small molecule inhibitors and their therapeutic applications.
- Consolidation of drug discovery approaches targeting key pathway nodes.
Main Results:
- Over 10 small molecule drugs targeting the JAK-STAT pathway have been approved, with many more in clinical trials.
- JAK inhibitors like tofacitinib and ruxolitinib demonstrate efficacy in treating conditions such as rheumatoid arthritis and myelofibrosis.
- Diverse strategies are employed to modulate JAK-STAT signaling, from receptor interactions to transcription factor activation.
Conclusions:
- The JAK-STAT pathway presents significant therapeutic potential for various diseases.
- Small molecule interventions targeting the JAK-STAT pathway are a rapidly advancing area of pharmaceutical research.
- Continued research into JAK-STAT signaling modulation is expected to yield innovative treatments for a range of conditions.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:22Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K